CSBR: Champions Oncology, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 61.85
Enterprise Value ($M) 58.96
Book Value ($M) -0.33
Book Value / Share -0.02
Price / Book -186.30
NCAV ($M) -12.09
NCAV / Share -0.89
Price / NCAV -5.12

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.12
Return on Equity (ROE) -36.53

Liquidity (mrq)
Quick Ratio 0.69
Current Ratio 0.69

Balance Sheet (mrq) ($M)
Current Assets 13.18
Assets 24.93
Liabilities 25.27
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
8 days ago 13G/A West Elk Partners, LP 6.49 -19.28
05-06 13D/A New Enterprise Associates 14, L.P. 12.60 -94.10
02-12 13G Tocqueville Asset Management L.p. 5.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-09-13 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-07-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-03-15 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2023-12-13 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-20 6,190 22,525 27.48
2024-11-19 6,322 9,918 63.74
2024-11-18 199 3,615 5.50

(click for more detail)

Similar Companies
CRDF – Cardiff Oncology, Inc. CRIS – Curis, Inc.
CRVO – CervoMed Inc. CSCI – COSCIENS Biopharma Inc.
CTXR – Citius Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.